Lipid-lowering treatment in coronary artery disease: A survey in an ambulatory outpatient clinic

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 12, 2001, Pages 534-538

  Harder, S ^a   Mohr, O ^a   Klepzig, H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOLOGY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG UTILIZATION; DYSLIPIDEMIA; EVALUATION; GENERAL PRACTITIONER; GERMANY; HEALTH SURVEY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; OUTPATIENT; PATIENT REFERRAL; PHARMACOEPIDEMIOLOGY; SYMPTOM; UNIVERSITY HOSPITAL;

EID: 0035202960     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39534     Document Type: Article

References (17)

1. Systematic review on the risk and benefit of different cholesterol-lowering interventions
2. From trial data to practical knowledge: Qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolemia
3. Growth in use of statins after trials is not targeted to most appropriate patients
4. Prescription of cardiovascular drugs in outpatient care: A survey of outpatients in a German University Hospital
5. The prescribing of lipid-lowering drugs during a 1-year period: Analysis of 7490 health insurance files
6. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials
7. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy
8. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
9. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
11. Pravastatin and coronary heart disease
12. Clinical outcomes in statin treatment trials: A meta-analysis
13. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
14. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
15. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases
16. Prevalence and treatment of hypercholesterolemia in patients with manifest vascular disease according to practice guidelines of the current cholesterol consensus
17. After 4S, CARE and LIPID - Is evidence-based medicine being practised?